– Proof-of-Concept Trial Confirms ZT-01’s Mechanism of Action in Restoring Glucagon Release in Patients with Type 1 Diabetes – –
Zucara Therapeutics Secures Additional Funding from GlycoNet and Mitacs for the Development of ZT-01
Zucara Therapeutics Secures Additional Funding from GlycoNet and Mitacs for the Development of ZT-01 – Second grants from GlycoNet and
Zucara Therapeutics Announces Publication of Preclinical Study Demonstrating ZT-01’s Ability to Restore Glucagon Release in Type 1 Diabetes
Zucara Therapeutics Announces Publication of Preclinical Study Demonstrating ZT-01’s Ability to Restore Glucagon Release in Type 1 Diabetes – ZT-01
Zucara Therapeutics Doses First Patients in Phase 1b Trial of ZT-01
Zucara Therapeutics Doses First Patients in Phase 1b Trial of ZT-01 – Proof-of-Concept Trial to Evaluate the Effect of ZT-01
Zucara Therapeutics Successfully Completes Single and Multiple Ascending Dose Phase 1 Trial of ZT-01
Zucara Therapeutics Successfully Completes Single and Multiple Ascending Dose Phase 1 Trial of ZT-01 Toronto, Canada, May 26, 2021 –
Zucara Therapeutics Expands ZT-01 Development Program to Type 2 Diabetes
Zucara Therapeutics Expands ZT-01 Development Program to Type 2 Diabetes – ZT-01 Development for T2D to be Supported by Nearly
Zucara Therapeutics Doses First Subject in Phase 1 Trial of ZT-01
Zucara Therapeutics Doses First Subject in Phase 1 Trial of ZT-01 – Phase 1 Trial to Evaluate ZT-01 for the
Zucara Therapeutics Announces US$21 Million Series A Financing
Zucara Therapeutics Announces US$21 Million Series A Financing – Proceeds to Fund Development of ZT-01 Through Phase 2 Clinical Trials
Zucara Therapeutics Presents New Data at European Association for the Study of Diabetes
Dr. Richard Liggins, Chief Scientific Officer, presenting at EASD in Barcelona. TORONTO, Canada and BARCELONA, Spain: Zucara Therapeutics Inc., a
Zucara Therapeutics Secures Grant from GlycoNet to Expand and Validate their Drug Therapy Model for Type 1 Diabetes to Type 2 Diabetes

Toronto & Vancouver, Canada: Zucara Therapeutics Inc., a life sciences company developing the first once-daily therapeutic to prevent hypoglycemia in